ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

NCT04393038 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

509

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis concludes that the study is futile

Conditions

COVID-19

Interventions

DRUG: ABX464
DRUG: Placebo

Sponsor

Abivax S.A.